<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00606775</url>
  </required_header>
  <id_info>
    <org_study_id>TN1966220</org_study_id>
    <nct_id>NCT00606775</nct_id>
  </id_info>
  <brief_title>The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy</brief_title>
  <official_title>Carvedilol for the Prevention of Minor Cardiac Damage and Cardiac Function in Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzuka Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nagoya University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Suzuka Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose This cardiac dysfunction in patients with Duchenne muscular dystrophy is associated
      with minor cardiac damage as indicated by elevation of plasma cardiac troponin I (cTnI). The
      purpose of this study is to investigate whether the administration of Carvedilol can suppress
      the minor cardiac damage and prevent deterioration of cardiac function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The life span in patients with Duchenne muscular dystrophy has been extending due to the
      development of artificial respiratory devices. According to that, the ratio of cardiac
      dysfunction as a cause of death has been increasing. This cardiac dysfunction was associated
      with minor cardiac damage as indicated by elevation of plasma cardiac troponin I (cTnI).
      Furthermore, and the detection rate of cTnI plasma as revealed to be correlated with the
      deterioration speed of LV dysfunction assessed by serial echocardiography measurements.
      Accordingly, if this minor cardiac damage is suppressed, it is postulated that the
      progression of cardiac dysfunction can be stopped. In the cases with ventricular arrhythmia
      and tachycardia, we found plasma cTnI became undetectable after administration of
      beta-blocker. Accordingly, we investigate whether administration of beta-blocker, carvedilol
      can persistently suppress the minor cardiac damage and lead to suppress the deterioration of
      LV function. Note that his study preventive study for preserved to moderate LV dysfunction
      and is not intended to the beta-blocker treatment for severe LV dysfunction. Because we
      assume that the mechanism of elevation of cTnI is different; spontaneous in preserved to mild
      LV dysfunction in patients but LV wall stress in severe LV dysfunction in patients with
      Duchenne muscular dystrophy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2007</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The suppression of minor cardiac damage indicated as elevation of plasma cTnI</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular function deterioration assessed by echocardiography In-hospital mortality for cardiac dysfunction In-hospital mortality for any cause Overall mortality</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <condition>Cardiomyopathies</condition>
  <arm_group>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>2.5-5mg/day</description>
    <arm_group_label>Carvedilol</arm_group_label>
    <other_name>Artist, Daich-Sankyo Co.Ltd</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male patients with Duchenne muscular dystrophy are required to meet the following criteria:

          1. Aged ８ to 45 years

          2. Positive plasma cardiac troponin I (0.06ng/mL) at least 4 blood measurement in every 3
             month.

          3. Left ventricular ejection fraction &gt;30% by echocardiography assessment

          4. Written informed consent

        Exclusion Criteria:

        Patients with the following conditions will be excluded from the study:

          1. Left ventricular ejection fraction &lt;30%

          2. No plasma cTnI elevation

          3. beta-blocker is already administered without measurement of plasma cTnI

          4. Contraindication against treatment with β blockers

          5. Any other serious disease that could potentially complicate the management and
             follow-up protocols
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takao Nishizawa, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Nagoya University Graduate School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takao Nishizawa, MD,PhD</last_name>
    <phone>+81-52-744-2150</phone>
    <email>nishizta@med.nagoya-u.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fumihiko Yasuma, MD,PhD</last_name>
    <phone>+81-59-378-1321</phone>
    <email>yasuma@suzuka.go.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Suzuka Hospial</name>
      <address>
        <city>Suzuka</city>
        <state>Mie</state>
        <zip>513-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takao Nishizawa, MD. PhD</last_name>
      <phone>+81-52-744-2150</phone>
      <email>nishizta@med.nagoya-u.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Fumihiko Yasuma, MD. PhD</last_name>
      <phone>+81-593-78-0337</phone>
      <email>yasuma@suzuka.go.jp</email>
    </contact_backup>
    <investigator>
      <last_name>Fumihiko Yasuma, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Toshimitsu Mori, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Motoko Sakai, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Satoshi Kuru, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seigo Kimura, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Takuya Tamura, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kentaro Sahashi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rei Shibata, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Taiki Ohashi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Sato Y, Yamada T, Taniguchi R, Nagai K, Makiyama T, Okada H, Kataoka K, Ito H, Matsumori A, Sasayama S, Takatsu Y. Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation. 2001 Jan 23;103(3):369-74.</citation>
    <PMID>11157687</PMID>
  </reference>
  <reference>
    <citation>Yasuma F, Konagaya M, Sakai M, Kuru S, Kawamura T. A new lease on life for patients with Duchenne muscular dystrophy in Japan. Am J Med. 2004 Sep 1;117(5):363.</citation>
    <PMID>15336589</PMID>
  </reference>
  <reference>
    <citation>Hunsaker RH, Fulkerson PK, Barry FJ, Lewis RP, Leier CV, Unverferth DV. Cardiac function in Duchenne's muscular dystrophy. Results of 10-year follow-up study and noninvasive tests. Am J Med. 1982 Aug;73(2):235-8.</citation>
    <PMID>7114081</PMID>
  </reference>
  <reference>
    <citation>Jefferies JL, Eidem BW, Belmont JW, Craigen WJ, Ware SM, Fernbach SD, Neish SR, Smith EO, Towbin JA. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation. 2005 Nov 1;112(18):2799-804. Epub 2005 Oct 24.</citation>
    <PMID>16246949</PMID>
  </reference>
  <reference>
    <citation>Ishikawa Y, Bach JR, Minami R. Cardioprotection for Duchenne's muscular dystrophy. Am Heart J. 1999 May;137(5):895-902.</citation>
    <PMID>10220639</PMID>
  </reference>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2008</study_first_submitted>
  <study_first_submitted_qc>February 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2008</study_first_posted>
  <last_update_submitted>February 4, 2008</last_update_submitted>
  <last_update_submitted_qc>February 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2008</last_update_posted>
  <responsible_party>
    <name_title>Takao Nishizawa</name_title>
    <organization>Department of Cardiology, Nagoya Universtiy Graduate School of Medicine</organization>
  </responsible_party>
  <keyword>Adrenergic beta-Antagonists</keyword>
  <keyword>Duchenne Muscular Dystrophy</keyword>
  <keyword>Cardiomyopathies</keyword>
  <keyword>Troponin I</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

